Literature DB >> 20351870

Evaluation of the PharmGKB knowledge base as a resource for efficiently assessing the clinical validity and utility of pharmacogenetic assays.

Kensaku Kawamoto1, Lori A Orlando, Deepak Voora, David F Lobach, Scott Joy, Alex Cho, Geoffrey S Ginsburg.   

Abstract

Prior to clinical use, pharmacogenetic tests should be systematically evaluated for their clinical validity and utility. Here, we evaluated whether the publicly available, online Pharmacogenomics Knowledge Base (PharmGKB) could facilitate such assessments by efficiently identifying relevant peer-reviewed manuscripts. The search targets were 55 manuscripts regarding clinical validity and utility included in systematic reviews of warfarin, antidepressant, and irinotecan pharmacogenetics. When direct inclusion in PharmGKB was the search criterion, recall was 33% and precision was 16%. However, recall increased to 78% when citation within a PharmGKB-identified manuscript was added as a search criterion. These recalled manuscripts accounted for 87% of the study subjects, and domain experts determined that the omission of the remaining manuscripts was unlikely to have changed the conclusions of the reviews. Thus, we conclude that PharmGKB can facilitate the systematic assessment of pharmacogenetic assays through the efficient identification of relevant peer-reviewed manuscripts.

Entities:  

Mesh:

Year:  2009        PMID: 20351870      PMCID: PMC2815454     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  8 in total

1.  Pharmacogenomics--drug disposition, drug targets, and side effects.

Authors:  William E Evans; Howard L McLeod
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 2.  Rapid ACCE: experience with a rapid and structured approach for evaluating gene-based testing.

Authors:  James M Gudgeon; Monica R McClain; Glenn E Palomaki; Marc S Williams
Journal:  Genet Med       Date:  2007-07       Impact factor: 8.822

3.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors:  J Lazarou; B H Pomeranz; P N Corey
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

Review 4.  Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).

Authors:  David B Matchar; Mugdha E Thakur; Iris Grossman; Douglas C McCrory; Lori A Orlando; David C Steffens; David B Goldstein; Kathryn E Cline; Rebecca N Gray
Journal:  Evid Rep Technol Assess (Full Rep)       Date:  2007-01

Review 5.  A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.

Authors:  Monica R McClain; Glenn E Palomaki; Margaret Piper; James E Haddow
Journal:  Genet Med       Date:  2008-02       Impact factor: 8.822

6.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Authors:  Steven M Teutsch; Linda A Bradley; Glenn E Palomaki; James E Haddow; Margaret Piper; Ned Calonge; W David Dotson; Michael P Douglas; Alfred O Berg
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

Review 7.  Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.

Authors:  Glenn E Palomaki; Linda A Bradley; Michael P Douglas; Katherine Kolor; W David Dotson
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

8.  The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge.

Authors:  Tina Hernandez-Boussard; Michelle Whirl-Carrillo; Joan M Hebert; Li Gong; Ryan Owen; Mei Gong; Winston Gor; Feng Liu; Chuong Truong; Ryan Whaley; Mark Woon; Tina Zhou; Russ B Altman; Teri E Klein
Journal:  Nucleic Acids Res       Date:  2007-11-21       Impact factor: 16.971

  8 in total
  1 in total

1.  Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support.

Authors:  Casey Lynnette Overby; Peter Tarczy-Hornoch; James I Hoath; Ira J Kalet; David L Veenstra
Journal:  BMC Bioinformatics       Date:  2010-10-28       Impact factor: 3.169

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.